Movatterモバイル変換


[0]ホーム

URL:


PE20230986A1 - Anticuerpo que se une a vegf-a y ang2, y metodos de uso - Google Patents

Anticuerpo que se une a vegf-a y ang2, y metodos de uso

Info

Publication number
PE20230986A1
PE20230986A1PE2023000941APE2023000941APE20230986A1PE 20230986 A1PE20230986 A1PE 20230986A1PE 2023000941 APE2023000941 APE 2023000941APE 2023000941 APE2023000941 APE 2023000941APE 20230986 A1PE20230986 A1PE 20230986A1
Authority
PE
Peru
Prior art keywords
methods
ang2
antibody
binds vegf
vegf
Prior art date
Application number
PE2023000941A
Other languages
English (en)
Inventor
Sabine Imhof-Jung
Sebastian Fenn
Joerg Moelleken
Michael Molhoj
Christian Schantz
Janina Speck
Christoph Ullmer
Barbara Weiser
Guido Hartmann
Roland Beckmann
Kristian Hobolt Jensen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La RochefiledCriticalHoffmann La Roche
Publication of PE20230986A1publicationCriticalpatent/PE20230986A1/es

Links

Classifications

Landscapes

Abstract

La presente invencion se refiere a anticuerpos anti-VEGF-A/anti-ANG2, por ejemplo, en forma de un fragmento Fab biespecifico, y sus metodos de uso
PE2023000941A2020-09-042021-09-02Anticuerpo que se une a vegf-a y ang2, y metodos de usoPE20230986A1 (es)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
EP201946102020-09-04
EP202095912020-11-24
PCT/EP2021/074195WO2022049165A1 (en)2020-09-042021-09-02Antibody that binds to vegf-a and ang2 and methods of use

Publications (1)

Publication NumberPublication Date
PE20230986A1true PE20230986A1 (es)2023-06-21

Family

ID=77750299

Family Applications (1)

Application NumberTitlePriority DateFiling Date
PE2023000941APE20230986A1 (es)2020-09-042021-09-02Anticuerpo que se une a vegf-a y ang2, y metodos de uso

Country Status (16)

CountryLink
US (2)US11732036B2 (es)
EP (1)EP4208201A1 (es)
JP (2)JP7158626B1 (es)
KR (1)KR20230061458A (es)
CN (1)CN116323663A (es)
AU (1)AU2021335509A1 (es)
CA (1)CA3193163A1 (es)
CL (1)CL2023000595A1 (es)
CO (1)CO2023004251A2 (es)
CR (1)CR20230114A (es)
IL (1)IL300616A (es)
MX (1)MX2023002496A (es)
PE (1)PE20230986A1 (es)
TW (1)TW202227487A (es)
WO (1)WO2022049165A1 (es)
ZA (1)ZA202302084B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
KR20230061458A (ko)*2020-09-042023-05-08에프. 호프만-라 로슈 아게Vegf-a 및 ang2에 결합하는 항체 및 사용 방법
WO2024085606A1 (ko)*2022-10-202024-04-25(주)니오테스바이오인간 안지오포이에틴-2에 특이적으로 결합하는 제1 항원 결합 부위를 포함하는 이중특이적 항체 및 그 응용

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US830930A (en)1905-11-221906-09-11E & T Fairbanks & CoWeighing-scale.
US4816567A (en)1983-04-081989-03-28Genentech, Inc.Recombinant immunoglobin preparations
IL85035A0 (en)1987-01-081988-06-30Int Genetic EngPolynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en)1987-03-181990-08-16Sb2, Inc.Altered antibodies
US7018809B1 (en)1991-09-192006-03-28Genentech, Inc.Expression of functional antibody fragments
CA2163345A1 (en)1993-06-161994-12-22Susan Adrienne MorganAntibodies
US5789199A (en)1994-11-031998-08-04Genentech, Inc.Process for bacterial production of polypeptides
US5840523A (en)1995-03-011998-11-24Genetech, Inc.Methods and compositions for secretion of heterologous polypeptides
US5869046A (en)1995-04-141999-02-09Genentech, Inc.Altered polypeptides with increased half-life
US6267958B1 (en)1995-07-272001-07-31Genentech, Inc.Protein formulation
GB9603256D0 (en)1996-02-161996-04-17Wellcome FoundAntibodies
US6171586B1 (en)1997-06-132001-01-09Genentech, Inc.Antibody formulation
PT994903E (pt)1997-06-242005-10-31Genentech IncMetodos e composicoes para glicoproteinas galactosiladas
WO1999022764A1 (en)1997-10-311999-05-14Genentech, Inc.Methods and compositions comprising glycoprotein glycoforms
WO1999051642A1 (en)1998-04-021999-10-14Genentech, Inc.Antibody variants and fragments thereof
US6194551B1 (en)1998-04-022001-02-27Genentech, Inc.Polypeptide variants
AU3657899A (en)1998-04-201999-11-08James E. BaileyGlycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6596860B1 (en)1998-07-232003-07-22Cooperatieve Verkoop-En Productievereniging Van Aardappelmeel En Derivaten Avebe B.A.Adhesive composition
US6737056B1 (en)1999-01-152004-05-18Genentech, Inc.Polypeptide variants with altered effector function
HUP0104865A3 (en)1999-01-152004-07-28Genentech IncPolypeptide variants with altered effector function
NZ581474A (en)2001-08-032011-04-29Glycart Biotechnology AgAntibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ATE430580T1 (de)2001-10-252009-05-15Genentech IncGlycoprotein-zusammensetzungen
US20040093621A1 (en)2001-12-252004-05-13Kyowa Hakko Kogyo Co., LtdAntibody composition which specifically binds to CD20
US20040259150A1 (en)2002-04-092004-12-23Kyowa Hakko Kogyo Co., Ltd.Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
EP1502603A4 (en)2002-04-092006-12-13Kyowa Hakko Kogyo Kk AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
ES2362419T3 (es)2002-04-092011-07-05Kyowa Hakko Kirin Co., Ltd.Células con depresión o deleción de la actividad de la proteína que participa en el transporte de gdp-fucosa.
MXPA04009924A (es)2002-04-092005-07-01Kyowa Hakko Kogyo KkCelulas de genoma modificado.
WO2003085118A1 (fr)2002-04-092003-10-16Kyowa Hakko Kogyo Co., Ltd.Procede de production de composition anticorps
US7361740B2 (en)2002-10-152008-04-22Pdl Biopharma, Inc.Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20040101920A1 (en)2002-11-012004-05-27Czeslaw RadziejewskiModification assisted profiling (MAP) methodology
PL212899B1 (pl)2002-12-162012-12-31Genentech IncHumanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku
EP2264151B1 (en)2003-01-222016-04-20Roche Glycart AGFusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function
US7871607B2 (en)2003-03-052011-01-18Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP2357201B1 (en)2004-04-132017-08-30F. Hoffmann-La Roche AGAnti-P-selectin antibodies
TWI309240B (en)2004-09-172009-05-01Hoffmann La RocheAnti-ox40l antibodies
ES2669510T3 (es)2004-09-232018-05-28Genentech, Inc.Anticuerpos y conjugados modificados por ingeniería genética con cisteína
JO3000B1 (ar)2004-10-202016-09-05Genentech Incمركبات أجسام مضادة .
WO2006082515A2 (en)2005-02-072006-08-10Glycart Biotechnology AgAntigen binding molecules that bind egfr, vectors encoding same, and uses thereof
DK2059533T3 (da)2006-08-302013-02-25Genentech IncMultispecifikke antistoffer
DE102007001370A1 (de)2007-01-092008-07-10Curevac GmbhRNA-kodierte Antikörper
US9266967B2 (en)2007-12-212016-02-23Hoffmann-La Roche, Inc.Bivalent, bispecific antibodies
US8242247B2 (en)2007-12-212012-08-14Hoffmann-La Roche Inc.Bivalent, bispecific antibodies
US20090162359A1 (en)2007-12-212009-06-25Christian KleinBivalent, bispecific antibodies
JP5577354B2 (ja)2009-01-292014-08-20フォーサイト・ビジョン フォー・インコーポレーテッド治療装置
SG174378A1 (en)2009-03-202011-10-28Genentech IncBispecific anti-her antibodies
SG185428A1 (en)2010-06-082012-12-28Genentech IncCysteine engineered antibodies and conjugates
CN103209664A (zh)2010-08-052013-07-17弗赛特影像4股份有限公司可植入的治疗装置
US20130274692A1 (en)2010-08-052013-10-17Yair AlsterSubconjuctival implant for posterior segment drug delivery
AU2012234335B2 (en)2011-03-292016-09-01Roche Glycart AgAntibody Fc variants
WO2012163520A1 (en)2011-05-272012-12-06DutalysDual targeting
PT2755600T (pt)2011-09-162021-04-19Forsight Vision4 IncAparelhos de troca de fluidos
WO2013116061A1 (en)2012-02-032013-08-08Forsight Vision4, Inc.Insertion and removal methods and apparatus for therapeutic devices
EP2814587B1 (en)2012-02-152018-05-02F.Hoffmann-La Roche AgFc-receptor based affinity chromatography
EP2819788B1 (en)2012-02-272018-08-22Amunix Operating Inc.Xten conjugate compositions and methods of making same
PT2872534T (pt)*2012-07-132018-10-26Roche Glycart AgAnticorpos biespecíficos anti-vegf/anti-ang-2 e a sua utilização no tratamento de doenças oculares vasculares
SG10201800492PA (en)2013-04-292018-03-28Hoffmann La RocheHuman fcrn-binding modified antibodies and methods of use
KR20150063847A (ko)*2013-12-022015-06-10삼성전자주식회사항 VEGF-A/항 Ang2 이중 특이 항체
US20160302965A1 (en)2013-12-062016-10-20Forsight Vision4, Inc.Implantable therapeutic devices
CA2932364A1 (en)*2014-01-152015-07-23F. Hoffmann-La Roche AgFc-region variants with improved protein a-binding
UA117289C2 (uk)2014-04-022018-07-10Ф. Хоффманн-Ля Рош АгМультиспецифічне антитіло
WO2016016299A1 (en)2014-07-292016-02-04F. Hoffmann-La Roche AgMultispecific antibodies
JP2017531620A (ja)2014-09-122017-10-26ジェネンテック, インコーポレイテッドシステイン操作抗体及びコンジュゲート
AR103477A1 (es)2015-01-282017-05-10Lilly Co EliCompuestos de vegfa / ang2
US11059885B2 (en)2016-05-132021-07-13Askgene Pharma Inc.Angiopoietin 2, VEGF dual antagonists
CN109863171B (zh)2016-08-232023-08-04免疫医疗有限公司抗vegf-a和抗ang2抗体及其用途
CN119770646A (zh)*2018-02-062025-04-08豪夫迈·罗氏有限公司眼科疾病的治疗
EP3775267A4 (en)2018-04-102022-05-18Askgene Pharma, Inc. NEW DUAL ANTAGONISTS OF VEGF AND ANGIOPOIETIN 2
MA54052A (fr)*2018-10-292022-02-09Hoffmann La RocheFormulation d'anticorps
SG11202106198YA (en)*2018-12-212021-07-29Hoffmann La RocheAntibody that binds to vegf and il-1beta and methods of use
KR20230061458A (ko)*2020-09-042023-05-08에프. 호프만-라 로슈 아게Vegf-a 및 ang2에 결합하는 항체 및 사용 방법

Also Published As

Publication numberPublication date
KR20230061458A (ko)2023-05-08
CL2023000595A1 (es)2023-10-06
CN116323663A (zh)2023-06-23
MX2023002496A (es)2023-03-09
JP7158626B1 (ja)2022-10-21
AU2021335509A1 (en)2023-03-09
JP2022191367A (ja)2022-12-27
ZA202302084B (en)2023-11-29
US20230374119A1 (en)2023-11-23
CO2023004251A2 (es)2023-06-30
IL300616A (en)2023-04-01
TW202227487A (zh)2022-07-16
JP7631276B2 (ja)2025-02-18
CA3193163A1 (en)2022-03-10
CR20230114A (es)2023-05-18
EP4208201A1 (en)2023-07-12
US20220073599A1 (en)2022-03-10
JP2022545849A (ja)2022-10-31
WO2022049165A1 (en)2022-03-10
US11732036B2 (en)2023-08-22

Similar Documents

PublicationPublication DateTitle
CL2020001974A1 (es)Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
CL2018002490A1 (es)Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866)
CO2023004251A2 (es)Anticuerpo que se une a vegf-a y ang2, y métodos de uso
CO2019009076A2 (es)Anticuerpos biespecíficos de unión específica a pd1 y lag3
CL2019001372A1 (es)Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x.
CO2018007355A2 (es)Proteínas de unión al antígeno bispecífico de anti-tl1a/anti-tnf-α y sus usos
CO2020004199A2 (es)Anticuerpos específicos cd47/pd-l1
MX2020012639A (es)Anticuerpos frente a entpd2, terapias de combinacion y metodos de uso de los anticuerpos y las terapias de combinacion.
CL2019001198A1 (es)Anticuerpo bioespecífico contra bcma y cd3 y un fármaco inmunológico para uso combinado en el tratamiento de mieloma múltiple.
CO2018000886A2 (es)Anticuerpos biespecíficos para pd1 y tim3
PE20151289A1 (es)Anticuerpos que se unen al tl1a y sus usos
PE20190227A1 (es)Anticuerpos especificos para la tau hiperfosforilada y sus metodos de uso
PE20230444A1 (es)Anticuerpos
MX2021000163A (es)Proteina de union al antigeno anti-steap1.
CL2021002792A1 (es)Anticuerpo monoclonal que se une específicamente a gitr
CL2023001509A1 (es)Anticuerpos multiespecíficos y combinaciones de anticuerpos
CO2021008755A2 (es)Anticuerpo que se une a vegf y a il-1beta y métodos de utilización
AR119382A1 (es)Anticuerpos de pre-direccionamiento y métodos de uso
CO2024015714A2 (es)Anticuerpo que se une a vegf-a e il6 y métodos de uso
AR110680A1 (es)Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x
CL2021001104A1 (es)Anticuerpo monoclonal que se une específicamente al antígeno cd20
AR119982A1 (es)Terapias de combinación con anticuerpos entpd2

[8]ページ先頭

©2009-2025 Movatter.jp